Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Genetic Disease
Clinical Trials: Hereditary Angioedema
A listing of clinical trials currently looking for volunteers to enroll in Hereditary Angioedema studies. Click on the closest city to find more detailed information on a research study in your area.
Arkansas
Little Rock : Little Rock Allergry and Asthma Clinical Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
California
Bell Gardens : Sunrise Clinical Research
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Granada Hills : Allergy & Asthma Institute of the Valley
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Los Angeles : Unidversity of California, Los Angeles David Geffen School of Medicine
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Orange : 705 West LaVeta
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Walnut Creek : Allergy & Asthma Clinical Research Inc.
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Colorado
Colorado Springs : Asthma and Allergy Associates, P.C.
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Colorodo Springs : Associate, Asthma & Allergy Associates, P.C. Updated
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Connecticut
Waterbury : Center for Allergy, Asthma & Immunology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Florida
Tampa : University of South Florida
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Tampa : University of South Florida Asthma
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Georgia
Columbus : Brookstone Clinical Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Illinois
Chicago : University Consultants in Allergry and Immunology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Indiana
Evansville : Deaconess Clinic Downtown
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Muncie : Muncie Allergy Ctr
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Maryland
Chevy Chase : Institute for Asthma and Allergy, PC
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Chevy Chase : Institute for Asthma and Allergy, P.C.
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Massachusetts
Boston : Boston Children's Hospital
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Chestnut Hill : Brigham and Women's Hospital
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Michigan
Ann Arbor : University of Michigan Health System Allergy Specialty Clinic
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Clinton Township : Asthma and Allergy Institute of Michigan
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Missouri
St. Louis : Washington University School of Medicine
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Nevada
Reno : University of Nevada School of Medicine - Department of Pediatrics
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
New Jersey
Iselin : Allergy Treatment Center of New Jersey
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
New York
Mineola : Winthrop University Hospital Clinical Trials Center
HAE - Patients diagnosed with Acute Hereditary Angioedema
View More »
Bronx :
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Mineola : Winthrop University Hospital
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
North Carolina
Ashville : Allergy Partners of Western North Carolina
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Sanford : Specialty Medical Clinic And Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Ohio
Cincinnati : Department of Internal Medicine, University of Cincinnati -MSB
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Columbus : Optimed Research, LTD
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Toledo : Reynolds Clinic
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Toledo : Toledo Institute of Clinical Research
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Oklahoma
Tulsa : Allergy Clinic of the Tulsa, Inc.
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Oregon
Lake Oswego : Allergy, Asthma and Dermatoligy Research Center, LLC Updated
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Pennsylvania
Hershey : Penn State University
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Hershey : Penn State University - Penn State Milton S. Hershey Medical Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Pittsburgh : Children's Hospital of Pittsburgh of UPMC
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Texas
Dallas : AARA Research Center
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Dallas : AARA Research Center
Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema
Dallas : AARA Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Utah
Salt Lake City : University of Utah, Department of Dermatology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Virginia
Norfolk : Children's Hospital of the King's Daughters
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Virginia Beach :
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Washington
Spokane : Marycliff Allergy Specialists
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Tacoma : Puget Sound Allergy, Asthma and Immunology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Canada
Hamilton : McMaster University
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Germany
Berlin : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Berlin : Charite University Dermatology Clinic and Allergy Center
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Berlin : ViroPharma Investigational Site Updated
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Berlin : Charité Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Berlin : ViroPharma Investigational Site
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
View More »
Essen : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Essen : ViroPharma Investigational Site
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
Frankfurt : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Frankfurt : Klinikum der Johann Wolfgang Goethe University
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Frankfurt : University Hospital Frankfurt
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Mainz : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Mainz : Johannes-Gutenberg University Clinical Research Center
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Munich : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Munich : ViroPharma Investigational Site Updated
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Munich : Klinikum Rechts der Isar, Technical University Munich
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Hungary
Budapest : Heim Pal Childrens Hospital
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Budapest : ViroPharma Investigational Site Updated
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Israel
Haifa : Bnai Zion MEdical Center, Allergy and Immunology Institute
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Haifa : Bnei Zion Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Tel Aviv : Tel Aviv Sourasky Medical Center, Pulmonology and Allergy Unit
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Tel Hashomer : Sheba Medical Center Allergy and Immunology Angioedema Center
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Tel Hashomer : Sheba Medical Center
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
View More »
Tel-Aviv : Souraski Medical Center
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Italy
Milan : Hospital Luigi Sacco
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Naples : University of Naples Federico II, Dipartimento di Medicina Interna
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Netherlands
Poland
Krakow : Pediatric Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Lublin : Pediatric Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Romania
Targu Mures : Mures County Clinical Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Spain
Valencia : University Hospital, Pediatric Pulmonology and Allergy Unit
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
United Kingdom
London : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
